These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 33087494

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study.
    Ticau S, Aldinc E, Polydefkis M, Adams D, Coelho T, Ueda M, Hale C, Vest J, Nioi P, Patisiran Global OLE Collaborators.
    Amyloid; 2024 Mar; 31(1):1-11. PubMed ID: 37469249
    [Abstract] [Full Text] [Related]

  • 3. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
    Berends M, Brunger AF, Bijzet J, Kroesen BJ, Drost G, Lange F, Teunissen CE, In 't Veld S, Vrancken AF, Gans ROB, Hazenberg BPC, van der Zwaag PA, Nienhuis HLA.
    Amyloid; 2024 Jun; 31(2):132-141. PubMed ID: 38477065
    [Abstract] [Full Text] [Related]

  • 4. Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice.
    Carroll AS, Razvi Y, O'Donnell L, Veleva E, Heslegrave A, Zetterberg H, Vucic S, Kiernan MC, Rossor AM, Gillmore JD, Reilly MM.
    Amyloid; 2024 Jun; 31(2):95-104. PubMed ID: 38348665
    [Abstract] [Full Text] [Related]

  • 5. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
    Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ.
    J Clin Pharmacol; 2020 Jan; 60(1):37-49. PubMed ID: 31322739
    [Abstract] [Full Text] [Related]

  • 6. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    González-Duarte A, Berk JL, Quan D, Mauermann ML, Schmidt HH, Polydefkis M, Waddington-Cruz M, Ueda M, Conceição IM, Kristen AV, Coelho T, Cauquil CA, Tard C, Merkel M, Aldinc E, Chen J, Sweetser MT, Wang JJ, Adams D.
    J Neurol; 2020 Mar; 267(3):703-712. PubMed ID: 31728713
    [Abstract] [Full Text] [Related]

  • 7. Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.
    Minamisawa M, Claggett B, Adams D, Kristen AV, Merlini G, Slama MS, Dispenzieri A, Shah AM, Falk RH, Karsten V, Sweetser MT, Chen J, Riese R, Vest J, Solomon SD.
    JAMA Cardiol; 2019 May 01; 4(5):466-472. PubMed ID: 30878017
    [Abstract] [Full Text] [Related]

  • 8. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
    Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T, patisiran Global OLE study group.
    Lancet Neurol; 2021 Jan 01; 20(1):49-59. PubMed ID: 33212063
    [Abstract] [Full Text] [Related]

  • 9. Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study.
    Lin KP, Yang CC, Lee YC, Lee MJ, Vest J, Sweetser MT, White MT, Badri P, Hsieh ST, Chao CC.
    J Formos Med Assoc; 2024 Sep 01; 123(9):975-984. PubMed ID: 38548524
    [Abstract] [Full Text] [Related]

  • 10. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis.
    Louwsma J, Brunger AF, Bijzet J, Kroesen BJ, Roeloffzen WWH, Bischof A, Kuhle J, Drost G, Lange F, Kuks JBM, Gans ROB, Hazenberg BPC, Nienhuis HLA.
    Amyloid; 2021 Mar 01; 28(1):50-55. PubMed ID: 32883119
    [Abstract] [Full Text] [Related]

  • 11. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
    Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O.
    Circulation; 2019 Jan 22; 139(4):431-443. PubMed ID: 30586695
    [Abstract] [Full Text] [Related]

  • 12. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Merkel M, Danese D, Chen C, Wang J, Wu A, Yang H, Lin H.
    Expert Opin Pharmacother; 2023 Jan 22; 24(10):1205-1214. PubMed ID: 37219406
    [Abstract] [Full Text] [Related]

  • 13. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Planté-Bordeneuve V, Lin H, Gollob J, Agarwal S, Betts M, Fahrbach K, Chitnis M, Polydefkis M.
    Expert Opin Pharmacother; 2019 Mar 22; 20(4):473-481. PubMed ID: 30489166
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Labeyrie C, Merkel M, Sethi S, Popadic L, Yang H, Sweetser MT, Lin H, Adams D.
    Eur J Neurol; 2024 Sep 22; 31(9):e16384. PubMed ID: 38988097
    [Abstract] [Full Text] [Related]

  • 15. Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy.
    Gentile L, Mazzeo A, Briani C, Casagrande S, De Luca M, Fabrizi GM, Gagliardi C, Gemelli C, Forcina F, Grandis M, Guglielmino V, Iabichella G, Leonardi L, Lozza A, Manganelli F, Mussinelli R, My F, Occhipinti G, Fenu S, Russo M, Romano A, Salvalaggio A, Tagliapietra M, Tozza S, Palladini G, Obici L, Luigetti M.
    Neurol Sci; 2024 Sep 22; 45(9):4563-4571. PubMed ID: 38622453
    [Abstract] [Full Text] [Related]

  • 16. Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial.
    Quan D, Obici L, Berk JL, Ando Y, Aldinc E, White MT, Adams D.
    Amyloid; 2023 Mar 22; 30(1):49-58. PubMed ID: 36120830
    [Abstract] [Full Text] [Related]

  • 17. Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Gorevic P, Franklin J, Chen J, Sajeev G, Wang JCH, Lin H.
    Expert Opin Pharmacother; 2021 Jan 22; 22(1):121-129. PubMed ID: 32892660
    [Abstract] [Full Text] [Related]

  • 18. Biomarkers of axonal damage to favor early diagnosis in variant transthyretin amyloidosis (A-ATTRv).
    González-Moreno J, Gragera-Martínez Á, Rodríguez A, Borrachero-Garro C, García-Garrido S, Barceló C, Manovel-Sánchez A, Ribot-Sansó MA, Ibargüen-González L, Gomila R, Muñoz-Beamud F, Losada-López I, Cisneros-Barroso E.
    Sci Rep; 2024 Jan 05; 14(1):581. PubMed ID: 38182630
    [Abstract] [Full Text] [Related]

  • 19. Serum neurofilament light chain levels correlate with small fiber related parameters in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
    Galosi E, Costanzo R, Forcina F, Morino S, Antonini G, Salvetti M, Lauletta A, Luigetti M, Romano A, Primiano G, Guglielmino V, Fionda L, Garibaldi M, Esposito N, Falco P, di Pietro G, Truini A, Leonardi L.
    Neurol Sci; 2024 Oct 05; 45(10):5023-5032. PubMed ID: 38700599
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.